RIOK3

Across TCGA pan-cancer cohorts, RIOK3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RIOK3 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RIOK3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RIOK3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, LUAD, and UCEC are the cancer types where RIOK3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.886	0.303	.007	31	view →
LUAD	OS	Median	All	0.751	1.000	.002	14	view →
UCEC	OS	Tertile	II,III,IV	1.000	0.583	.017	8	view →
GBM	DFS	Quartile	All	0.263	0.521	.010	5	view →
CCRCC	DFS	Median	III,IV	0.465	0.690	.046	1	view →
LSCC	OS	Median	All	0.855	0.714	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RIOK3–HNSC (DFS)

Open the HNSC breakdown →